drugset / Trial / NCT01064882

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

NCT01064882

Phase 2 Completed 104 enrolled Allergan
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of bimatoprost ophthalmic solution 0.005% or 0.015% compared with bimatoprost ophthalmic solution 0.03% once-daily application to the upper eyelid margins in increasing eyelash prominence

Timeline

Start
2010-03
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.005 % Topical
Subject Bimatoprost Other / unclassified 0.015 % Topical
Subject Bimatoprost Other / unclassified 0.03 % Topical